Abstracts tagged "Oncology"

Abstract Number: 2004 • ACR Convergence 2024
Rheumatic Complications Post-CAR-T Cell Therapy. Experience of a Single Center
Jose Alfredo Gomez-Puerta¹, Ana Monegal¹, Andrés Ponce², Pilar Peris³, Nuria Martínez⁴, Valentin Ortiz-Maldonado⁴, Ana Triguero⁴, Carlos Fernández de larrea⁴, Julio Delgado⁴, Raimon Sanmartí Sala¹ and Manuel Juan⁵, ¹Rheumatology Department, Hospital Clinic of Barcelona, Barcelona, Spain, ²Rheumatology Department, Hospital Clínic of Barcelona, Barcelona, Spain, ³Rheumatology Department, Hospital Clínic de Barcelona, Barcelona, Spain, ⁴Haematology Department, Hospital Clinic of Barcelona, Barcelona, Spain, ⁵Immunology Department, Hospital Clinic of Barcelona, Barcelona, Spain
Background/Purpose: CAR-T cell therapy is a promising treatment for a range of systemic autoimmune diseases such as systemic lupus erythematosus, systemic sclerosis, and antisynthetase syndrome,…
Abstract Number: 0486 • ACR Convergence 2024
Associations Between Frailty and Incident Cancer and Cancer-related Mortality in Veterans with Rheumatoid Arthritis
Bhavik Bansal¹, Aaron Baraff², Katherine Wysham³, James Andrews⁴, Bryant England⁵, Ted Mikuls⁵, Joshua Baker⁶, Kaleb Michaud⁵, Alexa Meara⁷, Una Makris⁸, Carolyn Presley⁹, ariela orkaby¹⁰ and Namrata Singh¹¹, ¹All India Institute of Medical Sciences, New Delhi, Delhi, India, ²VA PUGET SOUND SEATTLE, Seattle, WA, ³VA PUGET SOUND/UNIVERSITY OF WASHINGTON, Seattle, WA, ⁴University of Alabama at Birmingham, Birmingham, AL, ⁵University of Nebraska Medical Center, Omaha, NE, ⁶University of Pennsylvania, Philadelphia, PA, ⁷The Ohio State University Wexner Medical Center, COLUMBUS, OH, ⁸UT Southwestern Medical Center and Dallas VA, Dallas, TX, ⁹The Ohio State Medical Center, Columbus, OH, ¹⁰New England VA Geriatric Research Education and Clinical Center/Boston VA/Division of Aging, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, ¹¹University of Washington, Bellevue, WA
Background/Purpose: Rheumatoid arthritis (RA) is associated with an increased risk of cancer compared to the general population. Aging is one of the most important risk…
Abstract Number: 2117 • ACR Convergence 2024
The Risk of Medication-related Osteonecrosis of the Jaw (MRONJ) in a Patient with Osteoporosis Treated with Antiresorptive Therapy and Undergoing Dental Care Is Negligible with a CTX Threshold Above 260
Camille Ghio, Robinson Gravier-Dumonceau, Pierre Lafforgue, Roch Giorgi and Thao Pham, Assistance Publique-Hôpitaux de Marseille, Marseille, France
Background/Purpose: Although antiresorptive treatments, including bisphosphonates and denosumab, have demonstrated their efficacy in treating osteoporosis. However, osteonecrosis of the jaw has been reported as a…
Abstract Number: 0916 • ACR Convergence 2024
Isocitrate Dehydrogenase 2 Mutations Are Associated with Autoimmune Rheumatologic Diseases in Chronic Myelomonocytic Leukemia
Mahmut Kaymakci¹, Anuya Natu², Clifford Csizmar², Terra Lasho², Christy Finke², Abhishek Mangaonkar¹, Aref Al-Kali¹, Hassan Alkhateeb¹, Jenna Fernandez², Matthew Koster¹, Cornelia Weyand², Mrinal Patnaik¹ and Kenneth Warrington¹, ¹Mayo Clinic, Rochester, MN, ²Mayo Clinic, Rochester
Background/Purpose: Somatic mutations occurring in the hematopoietic system can be associated with concomitant hematologic and inflammatory diseases. Chronic myelomonocytic leukemia (CMML) is a hematologic neoplasm…
Abstract Number: 2287 • ACR Convergence 2024
Hydroxychloroquine and the Risk of Lymphoma Progression in Sjogren’s Disease: A Retrospective Case Control Study
Christine Xue¹, Monica Guma² and Katherine Nguyen², ¹UC San Diego, San Diego, CA, ²UC San Diego, San Diego
Background/Purpose: Sjogren's disease is an autoimmune disorder characterized by chronic lymphocytic inflammation of the salivary and lacrimal glands. Affected individuals are at heightened risk of…
Abstract Number: 1056 • ACR Convergence 2023
Immune Checkpoint Inhibitor Rechallenge in Patients Who Previously Experienced Immune-Related Inflammatory Arthritis: A Multicenter Observational Study
Alexandra Ladouceur¹, Gael Mouterde², Alice TISON³, Samuel Bitoun⁴, Sorilla Mary-Prey⁵, Caroline Dutriaux⁶, Emilie Gerard⁵, Anne Pham-Ledard⁵, Marie Beylot-Barry⁵, Maeva Zysman⁵, Rémi Veillon⁵, Charlotte Domblides⁷, Amaury Daste⁷, Marine Gross-Goupil⁷, Baptiste Sionneau⁷, Félix Lefort⁷, Mathieu Larroquette⁷, Thomas Barnetche⁸, Christophe Richez⁹, Marie-Elise Truchetet⁸, Thierry Schaeverbebke¹⁰ and Marie Kostine⁸, ¹Department of Rheumatology of McGill University and CHU-Bordeaux, Montréal, QC, Canada, ²CHU Lapeyronie, Montpellier, France, ³CHU de la Cavale Blanche, Brest, France, ⁴Université Paris-Saclay, Hôpital Bicêtre, Assistance Publique-Hôpitaux de Paris, FHU CARE, Inserm UMR 1184, Paris, France, ⁵Department of Dermatology, Bordeaux University Hospital, Bordeaux, France, ⁶CHU-Bordeaux, Bordeaux, France, ⁷Department of Medical Oncology, Bordeaux University Hospital, Bordeaux, France, ⁸Bordeaux University Hospital, Bordeaux, France, ⁹Université de Bordeaux, Bordeaux, France, ¹⁰University Hospital of Bordeaux, Bordeaux, France
Background/Purpose: Immune checkpoint inhibitors (ICI) improve overall survival in many cancer patients by activating their immune system. However, they can cause off-target immune-related adverse events…
Abstract Number: 1057 • ACR Convergence 2023
Melanoma and Combination Immune Checkpoint Inhibitors Are More Clearly Associated with the Development of Chronic Inflammatory Arthritis Than Pre-existing Autoimmune Disease: A Cross-Sectional Study of Administrative Health Data
Alexandra Ladouceur¹, Marie Hudson², Hassan Behlouli³, Jeffrey Curtis⁴, Louise Pilote³ and Sasha Bernatsky³, ¹Department of Rheumatology of McGill University and CHU-Bordeaux, Montréal, QC, Canada, ²McGill University, Montréal, QC, Canada, ³Research Institute of the McGill University Health Centre, Montreal, QC, Canada, ⁴University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Immune checkpoint inhibitors (ICIs) improve survival in many malignancies1, by augmenting the immune system's anti-tumor response. However, ICI can result in immune-related adverse events…
Abstract Number: 1058 • ACR Convergence 2023
Resolution of Immune Checkpoint Inhibitors-Induced Inflammatory Arthritis While Maintaining Active Treatment with Checkpoint Inhibitors
Alexandra Ladouceur¹, Thomas Barnetche², Sorilla Mary-Prey³, Caroline Dutriaux⁴, Emilie Gerard³, Anne Pham-Ledard³, Marie Beylot-Barry³, Maeva Zysman³, Rémi Veillon³, Charlotte Domblides⁵, Amaury Daste⁵, Marine Gross-Goupil⁵, Baptiste Sionneau⁵, Félix Lefort⁵, Mathieu Larroquette⁵, Christophe Richez⁶, Marie-Elise Truchetet², Thierry Schaeverbebke⁷ and Marie Kostine², ¹Department of Rheumatology of McGill University and CHU-Bordeaux, Montréal, QC, Canada, ²Bordeaux University Hospital, Bordeaux, France, ³Department of Dermatology, Bordeaux University Hospital, Bordeaux, France, ⁴CHU-Bordeaux, Bordeaux, France, ⁵Department of Medical Oncology, Bordeaux University Hospital, Bordeaux, France, ⁶Université de Bordeaux, Bordeaux, France, ⁷University Hospital of Bordeaux, Bordeaux, France
Background/Purpose: Immune checkpoint inhibitors (ICI) are a revolutionary treatment that boost a patient's own immune system to fight cancer. However, activation of the immune system…
Abstract Number: 1074 • ACR Convergence 2023
Baseline Clinical Features, but Not Shared Epitope or HLA B27, Predict Severe Outcomes for Immune Checkpoint Inhibitor-induced Inflammatory Arthritis
Laura Cappelli¹, omer Kamal², Michelle Jones³, Clifton Bingham⁴ and Ami Shah⁵, ¹Johns Hopkins School of Medicine, Baltimore, MD, ²St. Agnes Hospital, Baltimore, MD, ³Johns Hopkins University School of Medicine, Baltimore, MD, ⁴Johns Hopkins University, Baltimore, MD, ⁵Department of Medicine, Division of Rheumatology, Johns Hopkins University School of Medicine, Ellicott City, MD
Background/Purpose: Immune checkpoint inhibitors (ICI) can cause inflammatory arthritis (IA) of varying severity. Many patients with ICI-IA require immunosuppression beyond corticosteroids, but there is no…
Abstract Number: 1678 • ACR Convergence 2023
Comparative Safety of Biologic and Targeted Synthetic Disease Modifying Anti-Rheumatic Drugs for Cancer in Rheumatoid Arthritis
Xavier Sendaydiego¹, Laura Gold², Jean liew³, K Wysham⁴, Maureen Dubreuil⁵, James Andrews¹, Pankti Reid⁶, David Liew⁷, Radjiv Goulabchand⁸, Abha Singh⁹, Grant Hughes¹, Mathilde Pioro¹, Jeffrey Sparks¹⁰, Jeffrey Jarvik², Siddharth Singh⁹ and Namrata Singh¹¹, ¹University of Washington, Seattle, WA, ²Department of Radiology and University of Washington Clinical Learning, Evidence, and Research (CLEAR) Center for Musculoskeletal Disorders, Seattle, WA, ³Boston University, Boston, MA, ⁴VA Puget Sound/University of Washington, Seattle, WA, ⁵Department of Rheumatology, Boston University School of Medicine, Milton, MA, ⁶University of Chicago Medical Center, Chicago, IL, ⁷Austin Health, Heidelberg, Australia, ⁸St. Eloi Hospital, Department of Internal Medicine and Multi-Organic Diseases, Montpellier, France, ⁹University of California San Diego, San Diego, CA, ¹⁰Division of Rheumatology, Inflammation, and Immunity, Brigham and Women’s Hospital and Harvard Medical School, Boston, MA, ¹¹University of Washington, Bellevue, WA
Background/Purpose: In the ORAL Surveillance trial, cancer risk was higher among patients with rheumatoid arthritis (RA) on tofacitinib, a Janus kinase inhibitor (JAKi), compared to…
Abstract Number: 2015 • ACR Convergence 2023
Synergistic Effect Between Denosumab and Immune Checkpoint Inhibitors : A Retrospective Study of 268 Patients with Bone Metastases
Emmanuel Massy¹, Etienne Mabrut¹, Sabine Mainbourg² and Cyrille Confavreux¹, ¹Centre Expert des Métastases Osseuses (CEMOS) - Service de Rhumatologie, Centre Hospitalier Lyon-Sud, Hospices Civils de Lyon, Université de Lyon, INSERM UMR 1033-LYOS, Lyon, France, ²Service de médecine interne et vasculaire, Centre Hospitalier Lyon Sud, Hospices Civils de Lyon, F-69495 Pierre-Bénite, Laboratoire de Biométrie et Biologie Evolutive, Université Lyon 1; CNRS, UMR 5558, 69622 Villeurbanne, Lyon, France
Background/Purpose: Bone is the third site of metastasis. Bone metastases are associated with poorer survival of patients and impaired quality of life with the occurrence…
Abstract Number: 2127 • ACR Convergence 2023
Associations Between Rheumatoid Arthritis, Frailty Status and Mortality in Older Adults with Bladder Cancer
Maya Swaminathan¹, Sarah Holt², John Gore², Yaw Nyame², Jonathan Wright², George Schade², Ami Shah³, Jeffrey Sparks⁴, Una Makris⁵, Petros Grivas⁶, Maria Suarez-Almazor⁷, Sarah Psutka² and Namrata Singh⁸, ¹University of Washington, Seattle, WA, ²Department of Urology, University of Washington, Seattle, WA, ³Department of Medicine, Division of Rheumatology, Johns Hopkins University School of Medicine, Ellicott City, MD, ⁴Division of Rheumatology, Inflammation, and Immunity, Brigham and Women’s Hospital and Harvard Medical School, Boston, MA, ⁵UT Southwestern Medical Center and Dallas VA, Dallas, TX, ⁶Division of Medical Oncology, Dept. of Medicine, UW; Clinical Research Division; Fred Hutchinson Cancer Center, Seattle, WA, ⁷MD Anderson Cancer Center, Houston, TX, ⁸University of Washington, Bellevue, WA
Background/Purpose: Rheumatoid arthritis (RA) is associated with an increased risk of developing certain cancers, including bladder cancer (Beydon et al. 20231). However, few studies have…
Abstract Number: 2139 • ACR Convergence 2023
Associations of Adipocytokines with Cancer Incidence in a Prospective Rheumatoid Arthritis Cohort
Namrata Singh¹, Aaron Baraff², K Wysham³, Punyasha Roul⁴, Grant Cannon⁵, Brian Sauer⁶, Geoffrey Thiele⁴, Bryant England⁴, Ted R Mikuls⁷ and Joshua Baker⁸, ¹University of Washington, Bellevue, WA, ²VA Puget Sound Seattle, Seattle, WA, ³VA Puget Sound/University of Washington, Seattle, WA, ⁴University of Nebraska Medical Center, Omaha, NE, ⁵University of Utah and Salt Lake City VA, Salt Lake City, UT, ⁶Salt Lake City VA/University of Utah, Salt Lake City, UT, ⁷Division of Rheumatology and Immunology, University of Nebraska Medical Center, Omaha, NE, ⁸University of Pennsylvania, Philadelphia, PA
Background/Purpose: A prior study suggested a higher risk of cancer mortality in patients with rheumatoid arthritis (RA) with higher levels of circulating leptin, an adipocytokine…
Abstract Number: 2512 • ACR Convergence 2023
Targeted Therapies for Severe Immune-related Adverse Events of Immune Checkpoint Inhibitors Are Not Associated with a Worse Prognosis
Jacques-Eric Gottenberg¹, Nathanaël Sedmak², Pierre Tran Ba Loc², Thibaut Fabacher², Thibaut Bahougne², Cécile Arnold², Guillaume Desjeux³, Hervé Servy⁴, Nicolas Meyer², Erik Sauleau², Raphaele Seror⁵ and Eden Sebbag⁶, ¹Rheumatology Department, Strasbourg University Hospital, Strasbourg, France, ²Hôpitaux Universitaires de Strasbourg, Strasbourg, France, ³e-Health Services Sanoia, Gemenos, France, ⁴e-Health Services Sanoia, La Ciotat, France, ⁵University Hospital Paris Saclay, Le Kremlin-Bicêtre, France, ⁶Université de Strasbourg, Strasbourg, France
Background/Purpose: In about 10% of patients, the immune response to immune checkpoint inhibitors (ICI) exceeds the anti-tumor response and leads to autoimmune complications (immune-related Adverse…
Abstract Number: 2513 • ACR Convergence 2023
Latent Class Analysis Identifies 2 Clinical Phenotypes of Immune Checkpoint Inhibitor-induced Inflammatory Arthritis
Laura Cappelli¹, Jamie Perin², Clifton Bingham³ and Ami Shah⁴, ¹Johns Hopkins School of Medicine, Baltimore, MD, ²Johns Hopkins University School of Medicine, Baltimore, MD, ³Johns Hopkins University, Baltimore, MD, ⁴Department of Medicine, Division of Rheumatology, Johns Hopkins University School of Medicine, Ellicott City, MD
Background/Purpose: : Immune checkpoint inhibitors (ICI) for cancer treatment can cause inflammatory arthritis (IA). ICI-IA is a heterogeneous entity affecting peripheral joints, tendons, and rarely…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].